Curcumin based combination therapy for anti-breast cancer: from in vitro drug screening to in vivo efficacy evaluation

Abstract

While drug resistance appears to be an inevitable problem of an increasing number of anticancer drugs in monotherapy, combination drug therapy has become a prosperous method to reduce the administered total drug dosages as well as overcome the drug resistance of carcinoma cells. Curcumin, considered to possess multi-faceted roles in cancer treatment according to its multiple anti-neoplastic mechanisms as a depressor of chemo-resistance, can significantly facilitate its anti-cancer functions and improve therapeutic effects via combination usage with a variety of other drugs with different reaction mechanisms. To explore this possibility, four anti-cancer chemotherapeutic agents that all possess a certain degree of drug resistance problems, including three tyrosine kinase inhibitors (erlotinib, sunitinib and sorafenib) that are acting on different cell pathways and a typical anticancer drug doxorubicin, were combined with curcumin individually to examine the synergistic anti-tumor effect both in vitro and in vivo. Results revealed that sunitinib combined with curcumin at the molar ratio of 0.46 yielded the most potent synergistic effect in vitro, and was therefore chosen for further animal evaluation. To further enhance the anti-cancer effect, bovine serum albumin (BSA) nanoparticles were utilized as a carrier to deliver the selected drug combination in situ. Preliminary in vivo findings confirmed our hypothesis of being able to maintain a similar injected drug ratio for prolonged time periods in tested animals by our approach, thereby maximizing the therapeutic potency yet minimizing the toxicity of these drugs. This work could open up a new avenue on combination drug therapy and realization the clinical utility of such drugs.

Key words： curcumin; sunitinib; synergistic effect; bovine serum albumin (BSA); nano-carriers

Acknowledgement

This work was supported in part by the National Natural Science Foundation of China (Grant Nos. 81402856, A3 project-81361140344, and 21402143). Professors Lee SJ and Shin MC are participants from the Korean A3 Foresight Program sponsored by NRF. This research was also partially sponsored by Tianjin Municipal Science and Technology Commission (15JCYBJC28700 and 15JCQNJC13600). This research was partially supported by grants from Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology Grants NRF-2015R1A6A3A01020598 and NRF-2015R1C1A1A02036781.

Electronic Supplementary Material

Supplementary material is available in the online version of this article at http://dx.doi.org/10.1007/s11705-016-1574-2 and is accessible for authorized users.

References

1 Basnet P, Skalko-Basnet N. Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules (Basel, Switzerland), 2011, 16(12): 4567–4598

2 Boyanapalli S S, Kong A N. Curcumin, the king of spices: Epigenetic regulatory mechanisms in the prevention of cancer, neurological and inflammatory diseases. Current Pharmacology Reports, 2015, 1(2): 129–139

3 Teiten M H, Dicato M, Diederich M. Curcumin as a regulator of epigenetic events. Molecular Nutrition & Food Research, 2013, 57(9): 1619–1629

4 Shehzad A, Lee Y S. Molecular mechanisms of curcumin action: Signal transduction. BioFactors (Oxford, England), 2013, 39(1): 27–36

5 Bose S, Panda A K, Mukherjee S, Sa G. Curcumin and tumor immune-editing: Resurrecting the immune system. Cell Division, 2015, 10(1): 6

6 Li Y, Zhang T. Targeting cancer stem cells by curcumin and clinical applications. Cancer Letters, 2014, 346(2): 197–205

7 Bordoloi D, Roy N K, Monisha J, Padmavathi G, Kunnumakkara A B. Multi-targeted agents in cancer cell chemosensitization: What we learnt from curcumin thus far. Recent Patents on Anti-cancer Drug Discovery, 2016, 11(1): 67–97

8 Saha S, Adhikary A, Bhattacharyya P, Das T, Sa G. Death by design: Where curcumin sensitizes drug-resistant tumors. Anticancer Research, 2012, 32(7): 2567–2584

9 Chang R, Sun L, Webster T J. Selective inhibition of MG-63 osteosarcoma cell proliferation induced by curcumin-loaded self-assembled arginine-rich-RGD nanospheres. International Journal of Nanomedicine, 2015, 10: 3351–3365

10 Collins H M, Abdelghany M K, Messmer M, Yue B, Deeves S E, Kindle K B, Mantelingu K, Aslam A, Winkler G S, Kundu T K, Heery D M. Differential effects of garcinol and curcumin on histone and p53 modifications in tumor cells. BMC Cancer, 2013, 13(1): 37

11 Bozic I, Reiter J G, Allen B, Antal T, Chatterjee K, Shah P, Moon Y S, Yaqubie A, Kelly N, Le D T, Lipson E J, Chapman P B, Diaz L A Jr, Vogelstein B, Nowak M A. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife, 2013, 2: e00747

12 Brahmbhatt M, Gundala S R, Asif G, Shamsi S A, Aneja R. Ginger phytochemicals exhibit synergy to inhibit prostate cancer cell proliferation. Nutrition and Cancer, 2013, 65(2): 263–272

13 Gotink K J, Verheul H M. Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? Angiogenesis, 2010, 13(1): 1–14

14 Shen G, Liu T, Wang Q, Jiang M, Shi J. Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA). Journal of Photochemistry and Photobiology B: Biology, 2015, 153: 380–390

15 Cao H, Wang Y, He X, Zhang Z, Yin Q, Chen Y, Yu H, Huang Y, Chen L, Xu M, Gu W, Li Y. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Molecular Pharmaceutics, 2015, 12(3): 922–931

16 Llovet J M, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J F, de Oliveira A C, Santoro A, Raoul J L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten T F, Galle P R, Seitz J F, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 2008, 359(4): 378–390

17 Desandes E. Survival from adolescent cancer. Cancer Treatment Reviews, 2007, 33(7): 609–615

18 Li S, Sun W, Wang H, Zuo D, Hua Y, Cai Z. Research progress on the multidrug resistance mechanism of osteosarcoma chemotherapy and reversal. Tumour Biology, 2015, 36(3): 1329–1338

19 Nedelcu T, Kubista B, Koller A, Sulzbacher I, Mosberger I, Arrich F, Trieb K, Kotz R, Toma C D. Livin and Bcl-2 expression in high-grade osteosarcoma. Journal of Cancer Research and Clinical Oncology, 2007, 134(2): 237–244

20 Rajkumar T, Yamuna M. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anti-Cancer Drugs, 2008, 19(3): 257–265

21 Guo L, Shen Y, Zhao X, Guo L, Yu Z, Wang D, Liu L, Liu J. Curcumin combined with oxaliplatin effectively suppress colorectal carcinoma in vivo through inducing apoptosis. Phytotherapy Research, 2015, 29(3): 357–365

22 Jonker M J, Svendsen C, Bedaux J J, Bongers M, Kammenga J E. Significance testing of synergistic/antagonistic, dose level-dependent, or dose ratio-dependent effects in mixture dose-response analysis. Environmental Toxicology and Chemistry, 2005, 24(10): 2701–2713

23 Hu C, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Therapeutic Delivery, 2010, 1(2): 323–334

24 Ashton J C. Drug combination studies and their synergy quantification using the Chou-Talalay Method-Letter. Cancer Research, 2015, 75(11): 2400

25 Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, Harvie P, Bermudes D, Mayer L. In vivo maintenance of synergistic cytarabine: Daunorubicin ratios greatly enhances therapeutic efficacy. Leukemia Research, 2009, 33(1): 129–139

26 Mayer L D, Harasym T O, Tardi P G, Harasym N L, Shew C R, Johnstone S A, Ramsay E C, Bally M B, Janoff A S. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Molecular Cancer Therapeutics, 2006, 5(7): 1854–1863

27 Farokhzad O C, Langer R. Impact of nanotechnology on drug delivery. ACS Nano, 2009, 3(1): 16–20

28 He H, David A, Chertok B, Cole A, Lee K, Zhang J, Wang J, HuangY, Yang V C. Magnetic nanoparticles for tumor imaging and therapy: A so-called theranostic system. Pharmaceutical Research, 2013, 30(10): 2445–2458

29 He H, Ye J, Sheng J, Wang J, Huang Y, Chen G, Wang J, Yang V C. Overcoming oral insulin delivery barriers: Application of cell penetrating peptide and silica-based nanoporous composites. Frontiers of Chemical Science and Engineering, 2013, 7(1): 9–19

30 He H, Liang Q, Shin M C, Lee K, Gong J, Ye J, Liu Q, Wang J, Yang V C. Significance and strategies in developing delivery systems for bio-macromolecular drugs. Frontiers of Chemical Science and Engineering, 2013, 7(4): 496–507

31 Parhi P, Mohanty C, Sahoo S K. Nanotechnology-based combinational drug delivery: An emerging approach for cancer therapy. Drug Discovery Today, 2012, 17(17-18): 1044–1052

32 Yamasaki K, Chuang V T, Maruyama T, Otagiri M. Albumin-drug interaction and its clinical implication. Biochimica et Biophysica Acta, 2013, 1830(12): 5435–5443

33 Lee H J, Bergen P J, Bulitta J B, Tsuji B, Forrest A, Nation R L, Li J. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrobial Agents and Chemotherapy, 2013, 57(8): 3738–3745

34 Allen T M, Cullis P R. Drug delivery systems: Entering the mainstream. Science, 2004, 303(5665): 1818–1822

35 Torchilin V P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS Journal, 2007, 9(2): E128–E147

36 Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. Journal of Controlled Release, 2008, 132(3): 171–183